Physician profile
Herbert Ladley
NPI 1174552467
$3,786.53
in general payments reported to CMS, 2019-2025
20 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $185 · 2021: $375 · 2022: $204 · 2023: $450 · 2024: $546 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,144.08 | 2019-2025 | Xience Skypoint, Ultreon, Xience Sierra |
| Hill-Rom Company, INC | $916.61 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $394.09 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $307.31 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $224.47 | 2019-2025 | |
| Abiomed | $185.24 | 2021 | |
| Boston Scientific Corporation | $100.37 | 2024-2025 | Watchman Flx, Rotapro |
| Pfizer INC. | $95.18 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $75.44 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $49.72 | 2019-2021 | |
| Edwards Lifesciences Corporation | $45.04 | 2021-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $39.75 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $36.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.64 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.97 | 2019 | |
| Heartflow, INC. | $21.09 | 2025 | |
| Merck Sharp & Dohme LLC | $17.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.79 | 2024 | |
| Philips North America LLC | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Ladley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.